ADAM vs REAX

ADAM's Piotroski F-Score of 4/9 indicates weak financial health, falling into the 'Weak' category, while the absence of an Altman Z-Score raises unquantified distress risk. Despite a high Graham Number of $15.59 and a current price of $7.87, the stock trades at a significant discount, but this is likely due to extreme financial instability. The company exhibits a 18,963.6% YoY revenue surge, yet earnings remain volatile and negative in multiple quarters, with a recent -36.1% Q/Q EPS decline. The 78.18% payout ratio on a highly erratic earnings base raises serious dividend sustainability concerns, undermining the 10.93% yield as a defensive feature.

REAX exhibits a stark divergence between fundamental health and growth potential. The deterministic baseline is weak, highlighted by a Piotroski F-Score of 2/9, indicating significant financial instability and poor operational efficiency. However, the company maintains strong top-line momentum with 44.10% YoY revenue growth and a very low Price/Sales ratio of 0.30. While analysts remain aggressively bullish with a target of $5.35, the technical trend is bearish and profitability remains elusive.